Astellas Pharma Completes Key Study on Roxadustat for Renal Anemia

Astellas Pharma ((ALPMF)), Astellas Pharma ((ALPMY)) announced an update on their ongoing clinical study.

Astellas Pharma has completed a post-marketing surveillance study titled ‘Specified Drug Use-Results Survey of EVRENZO® Tablets’ to evaluate the safety and efficacy of Roxadustat in patients with renal anemia. This non-interventional, prospective study aims to gather real-world data on the incidence of thromboembolism and other safety outcomes associated with Roxadustat treatment.

The intervention being tested is Roxadustat, an oral medication designed to treat renal anemia by stimulating erythropoiesis. It is marketed under the brand name EVRENZO®.

The study follows an observational cohort model with a prospective time perspective. It does not involve random allocation or masking, focusing instead on collecting data from patients in actual clinical settings to assess the drug’s performance post-marketing.

The study began on June 1, 2020, and was completed with the last update submitted on July 24, 2025. These dates are crucial as they mark the timeline for data collection and analysis, providing investors with a timeframe for when the study’s findings might impact market dynamics.

The completion of this study could influence Astellas Pharma’s stock performance by providing insights into Roxadustat’s safety profile, which may affect investor sentiment and market positioning. As the renal anemia treatment market is competitive, these findings could also impact the company’s standing relative to its competitors.

The study is now completed, with further details available on the ClinicalTrials portal.